441 related articles for article (PubMed ID: 7936651)
21. Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family.
Lomax ME; Barnes DM; Gilchrist R; Picksley SM; Varley JM; Camplejohn RS
Oncogene; 1997 Apr; 14(15):1869-74. PubMed ID: 9150393
[TBL] [Abstract][Full Text] [Related]
22. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.
Birch JM; Blair V; Kelsey AM; Evans DG; Harris M; Tricker KJ; Varley JM
Oncogene; 1998 Sep; 17(9):1061-8. PubMed ID: 9764816
[TBL] [Abstract][Full Text] [Related]
23. Germ-line splicing mutation of the p53 gene in a cancer-prone family.
Warneford SG; Witton LJ; Townsend ML; Rowe PB; Reddel RR; Dalla-Pozza L; Symonds G
Cell Growth Differ; 1992 Nov; 3(11):839-46. PubMed ID: 1467311
[TBL] [Abstract][Full Text] [Related]
24. Complex replication error causes p53 mutation in a Li-Fraumeni family.
Strauss EA; Hosler MR; Herzog P; Salhany K; Louie R; Felix CA
Cancer Res; 1995 Aug; 55(15):3237-41. PubMed ID: 7614454
[TBL] [Abstract][Full Text] [Related]
25. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
[TBL] [Abstract][Full Text] [Related]
26. Identification of novel TP53 mutations in familial and sporadic cancer cases of German and Swiss origin.
Bendig I; Mohr N; Kramer F; Weber BH
Cancer Genet Cytogenet; 2004 Oct; 154(1):22-6. PubMed ID: 15381368
[TBL] [Abstract][Full Text] [Related]
27. A novel p53 germline alteration identified in a late onset breast cancer kindred.
Sun XF; Johannsson O; Håkansson S; Sellberg G; Nordenskjöld B; Olsson H; Borg A
Oncogene; 1996 Jul; 13(2):407-11. PubMed ID: 8710380
[TBL] [Abstract][Full Text] [Related]
28. Novel germline mutation of the p53 tumor suppressor gene in a child with incidentally discovered adrenal cortical carcinoma.
Grayson GH; Moore S; Schneider BG; Saldivar V; Hensel CH
Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):341-7. PubMed ID: 7978053
[TBL] [Abstract][Full Text] [Related]
29. Germline TP53 mutations and Li-Fraumeni syndrome.
Varley JM
Hum Mutat; 2003 Mar; 21(3):313-20. PubMed ID: 12619118
[TBL] [Abstract][Full Text] [Related]
30. Dominant negative effect of a germ-line mutant p53: a step fostering tumorigenesis.
Srivastava S; Wang S; Tong YA; Hao ZM; Chang EH
Cancer Res; 1993 Oct; 53(19):4452-5. PubMed ID: 8402611
[TBL] [Abstract][Full Text] [Related]
31. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
[TBL] [Abstract][Full Text] [Related]
32. Germline mutations of the p53 tumor-suppressor gene in cancer-prone families: a review.
Soussi T; Leblanc T; Baruchel A; Schaison G
Nouv Rev Fr Hematol (1978); 1993 Feb; 35(1):33-6. PubMed ID: 8511038
[TBL] [Abstract][Full Text] [Related]
33. Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer.
Lehman TA; Haffty BG; Carbone CJ; Bishop LR; Gumbs AA; Krishnan S; Shields PG; Modali R; Turner BC
Cancer Res; 2000 Feb; 60(4):1062-9. PubMed ID: 10706125
[TBL] [Abstract][Full Text] [Related]
34. [Li-Fraumeni syndrome and germ-line mutations of the p53 gene].
Leblanc T; Soussi T
Arch Pediatr; 1994 Jan; 1(1):61-70. PubMed ID: 8087224
[TBL] [Abstract][Full Text] [Related]
35. Cancer risks from germ line tumor suppressor gene mutations.
Frebourg T; Malkin D; Friend S
Princess Takamatsu Symp; 1991; 22():61-70. PubMed ID: 1844252
[TBL] [Abstract][Full Text] [Related]
36. Genetic and functional studies of a germline TP53 splicing mutation in a Li-Fraumeni-like family.
Varley JM; Chapman P; McGown G; Thorncroft M; White GR; Greaves MJ; Scott D; Spreadborough A; Tricker KJ; Birch JM; Evans DG; Reddel R; Camplejohn RS; Burn J; Boyle JM
Oncogene; 1998 Jun; 16(25):3291-8. PubMed ID: 9681828
[TBL] [Abstract][Full Text] [Related]
37. p53 Germline mutation in a patient with Li-Fraumeni Syndrome and three metachronous malignancies.
Pötzsch C; Voigtländer T; Lübbert M
J Cancer Res Clin Oncol; 2002 Aug; 128(8):456-60. PubMed ID: 12200603
[TBL] [Abstract][Full Text] [Related]
38. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families.
Varley JM; McGown G; Thorncroft M; Santibanez-Koref MF; Kelsey AM; Tricker KJ; Evans DG; Birch JM
Cancer Res; 1997 Aug; 57(15):3245-52. PubMed ID: 9242456
[TBL] [Abstract][Full Text] [Related]
39. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations.
Gonzalez KD; Noltner KA; Buzin CH; Gu D; Wen-Fong CY; Nguyen VQ; Han JH; Lowstuter K; Longmate J; Sommer SS; Weitzel JN
J Clin Oncol; 2009 Mar; 27(8):1250-6. PubMed ID: 19204208
[TBL] [Abstract][Full Text] [Related]
40. Germ line BAX alterations are infrequent in Li-Fraumeni syndrome.
Barlow JW; Mous M; Wiley JC; Varley JM; Lozano G; Strong LC; Malkin D
Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1403-6. PubMed ID: 15298965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]